VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BHCBausch Health Companies Inc.
$4.76$1.8B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksBHCFinancials

Bausch Health Companies Inc. (BHC) Financials

30Y historyFree accessUpdated daily

Revenue growth remains stable at 10.5% in 2026Q1, yet gross margins have contracted significantly from over 70% in 2024 to 61.2% due to shifting product mixes.

BHC Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue10.55B10.45B9.63B8.76B8.12B8.43B8.03B8.6B8.38B8.72B9.67B10.44B8.2B5.77B3.48B2.46B1.15B820.43M757.18M842.82M1.07B935.54M886.54M823.72M788.02M583.26M309.17M176.5M112.8M82.4M66.4M
Revenue Growth %8.52%8.53%9.91%7.79%-3.68%5.07%-6.67%2.64%-3.94%-9.82%-7.35%27.34%42.22%65.66%41.28%114.94%39.7%8.35%-10.16%-21.27%14.42%5.53%7.63%4.53%35.11%88.65%75.17%56.47%36.89%24.1%222.33%
Cost of Goods Sold4.04B4.08B2.78B2.56B2.36B2.39B2.25B2.35B2.35B2.55B2.57B2.45B2.2B1.53B890.9M726.83M405.75M325.09M197.17M223.68M223.27M206.82M229.53M139.46M164.71M126M68.03M28.2M23.6M27.7M23.2M
COGS % of Revenue-39.1%28.9%29.22%29.1%28.39%28.02%27.32%28.05%29.21%26.6%23.42%26.87%26.51%25.6%29.5%35.4%39.62%26.04%26.54%20.86%22.11%25.89%16.93%20.9%21.6%22%15.98%20.92%33.62%34.94%
Gross Profit6.51B6.36B6.84B6.2B5.76B6.04B5.78B6.25B6.03B6.18B7.1B8B6B4.24B2.59B1.74B740.38M495.34M560.01M619.14M847.21M728.72M657.01M684.27M623.32M457.27M241.14M148.3M89.2M54.7M43.2M
Gross Margin %61.67%60.9%71.1%70.78%70.9%71.61%71.98%72.68%71.95%70.79%73.4%76.58%73.13%73.49%74.4%70.5%64.6%60.38%73.96%73.46%79.14%77.89%74.11%83.07%79.1%78.4%78%84.02%79.08%66.38%65.06%
Gross Profit Growth %--7.04%10.41%7.6%-4.64%4.53%-7.57%3.68%-2.38%-13.03%-11.19%33.33%41.54%63.62%49.11%134.56%49.47%-11.55%-9.55%-26.92%16.26%10.91%-3.98%9.78%36.31%89.63%62.6%66.26%63.07%26.62%163.41%
Operating Expenses4.09B4.14B5.3B5.24B5.31B5.59B5.1B6.45B8.41B6.07B7.67B6.47B4B4.65B2.51B1.31B344.86M192.75M365.7M430.46M602.55M403.92M550.83M679.47M321.29M205.63M110.75M72.8M40.1M17.2M19.7M
OpEx % of Revenue-39.62%55.03%59.78%65.31%66.28%63.56%75.04%100.39%69.62%79.25%61.95%48.73%80.59%72.06%53.02%30.09%23.49%48.3%51.07%56.29%43.18%62.13%82.49%40.77%35.26%35.82%41.25%35.55%20.87%29.67%
Selling, General & Admin3.44B3.5B3.28B2.9B2.53B2.49B2.37B2.55B2.47B2.58B2.78B2.7B2.03B1.31B756.1M584.31M329.16M178.6M188.92M161M238.43M231.11M274.55M242.77M165.7M110.1M58.09M29.6M17.6M14M10.2M
SG&A % of Revenue-33.49%34.11%33.06%31.15%29.55%29.49%29.69%29.51%29.6%28.76%25.86%24.71%22.64%21.72%23.72%28.72%21.77%24.95%19.1%22.27%24.7%30.97%29.47%21.03%18.88%18.79%16.77%15.6%16.99%15.36%
Research & Development650.07M640.01M634M604M530M473M485M516M442M369M469M440M266M156.8M79.1M174.89M157.56M14.15M92.84M118.12M95.47M88.88M72.5M86.57M52.15M51.02M52.66M33.1M17.5M07.5M
R&D % of Revenue-6.13%6.59%6.9%6.52%5.61%6.04%6%5.27%4.23%4.85%4.21%3.24%2.72%2.27%7.1%13.75%1.72%12.26%14.01%8.92%9.5%8.18%10.51%6.62%8.75%17.03%18.75%15.51%-11.3%
Other Operating Expenses311.38B1.74B2.25B2.63B2.25B3.38B5.5B3.12B4.42B3.33B1.7B3.18B0546.83M-141.85M083.93M151.34M268.64M83.93M203.77M350.13M103.44M44.51M010.1M5M3.2M2M
Operating Income2.42B2.22B1.55B963M454M450M676M-203M-2.38B102M-566M1.53B2B-409.5M79.69M525.32M-110.08M181.15M196.12M188.01M454.36M313.28M221.28M4.79M134.28M251.64M130.39M75.5M49.1M37.5M23.5M
Operating Margin %22.91%21.28%16.06%11%5.59%5.34%8.42%-2.36%-28.45%1.17%-5.85%14.62%24.4%-7.1%2.29%21.32%-9.6%22.08%25.9%22.31%42.44%33.49%24.96%0.58%17.04%43.14%42.17%42.78%43.53%45.51%35.39%
Operating Income Growth %-43.81%60.54%112.11%0.89%-33.43%433%91.48%-2437.25%118.02%-137.07%-23.69%588.64%-613.9%-84.83%577.19%-160.77%-7.63%4.31%-58.62%45.03%41.58%4516.71%-96.43%-46.64%92.99%72.7%53.77%30.93%59.57%803.85%
EBITDA3.62B3.45B2.81B2.23B1.85B2B2.5B1.87B435M2.96B2.3B3.99B3.62B1B1.07B1.12B144.42M330.41M299.54M288.78M550.1M420.98M314.96M272.27M224.25M319.5M151.92M85.6M54.1M40.7M25.5M
EBITDA Margin %34.28%33.05%29.23%25.43%22.75%23.74%31.16%21.76%5.19%33.93%23.78%38.25%44.09%17.35%30.63%45.49%12.6%40.27%39.56%34.26%51.39%45%35.53%33.05%28.46%54.78%49.14%48.5%47.96%49.39%38.4%
EBITDA Growth %28.88%22.73%26.31%20.51%-7.69%-19.95%33.6%330.34%-85.3%28.7%-42.41%10.48%261.39%-6.15%-4.88%675.91%-56.29%10.31%3.73%-47.5%30.67%33.66%15.68%21.41%-29.81%110.31%77.47%58.23%32.92%59.61%562.95%
D&A (Non-Cash Add-back)1.2B1.23B1.27B1.26B1.39B1.55B1.82B2.08B2.82B2.86B2.87B2.47B1.61B1.41B986.2M595.24M254.5M149.26M103.42M100.77M95.74M107.7M93.68M267.47M89.96M67.87M21.53M10.1M5M3.2M2M
EBIT2.42B2.22B1.87B1.62B1.48B1.71B1.31B1.34B500M555M1.21B2.64B2.3B1.44B803.1M306.11M-151.96M199.84M127.92M188.68M253.99M333.09M229.92M4.79M302.03M251.64M130.39M75.5M49.1M37.5M23.5M
Net Interest Income-1.64B-1.59B-1.35B-1.3B-1.45B-1.42B-1.52B-1.6B-1.67B-1.83B-1.83B-1.56B-966M-836.3M-475.6M-330.44M-83.01M-23.76M8.38M000000000000
Interest Income47.05M48.84M33M26M14M7M13M12M11M12M8M3.3M5M8.02M6M01.29M1.12M9.4M000000000000
Interest Expense1.69B1.64B1.39B1.33B1.46B1.43B1.53B1.61B1.69B1.84B1.84B1.56B971M844.32M481.6M330.44M84.31M25.42M1.02M000000000000
Other Income/Expense-3.34B-1.85B-1.38B-1.35B-583M-1.47B-1.61B-1.63B-1.77B-1.84B-1.87B-1.68B-947M-904.95M-473.91M0-126.18M-6.2M-86.42M20.73M-230.22M-33.71M-46.12M-49.14M-24.99M-148.91M-205.47M-8.8M-1.7M-400K-100K
Pretax Income-920.44M373.42M167M-390M-129M-1.02B-934M-1.84B-4.15B-1.74B-2.44B-155M1.05B-1.31B-394.23M-18M-236.26M174.96M109.7M208.74M224.14M279.56M175.16M-44.34M109.3M102.73M-75.08M66.7M47.4M37.1M23.4M
Pretax Margin %-8.72%3.57%1.74%-4.45%-1.59%-12.14%-11.64%-21.36%-49.57%-19.96%-25.17%-1.48%12.85%-22.8%-11.33%-0.73%-20.61%21.32%14.49%24.77%20.94%29.88%19.76%-5.38%13.87%17.61%-24.28%37.79%42.02%45.02%35.24%
Income Tax286.17M251.32M239M221M83M-87M-375M-54M-10M-4.14B-27M133M174M-450.78M-278.2M-177.56M-28.07M-1.5M-73M13.2M14.13M22.55M8.95M-4M21.5M15.29M9.36M4.2M2M1.9M700K
Effective Tax Rate %-31.09%67.3%143.11%-56.67%-64.34%8.5%40.15%2.94%0.24%238.08%1.11%-85.81%16.51%34.29%70.57%986.44%11.88%-0.86%-66.54%6.32%6.31%8.07%5.11%9.02%19.67%14.88%-12.47%6.3%4.22%5.12%2.99%
Net Income-1.19B159.75M-46M-592M-225M-948M-559M-1.78B-4.15B2.4B-2.41B-268.66M881M-866.14M-116.03M159.56M-208.19M176.46M199.9M195.54M210M246.44M160.99M-40.34M87.8M87.45M-147.98M62.5M45.4M35.2M22.7M
Net Margin %-11.27%1.53%-0.48%-6.76%-2.77%-11.24%-6.96%-20.73%-49.5%27.56%-24.9%-2.57%10.74%-15.02%-3.33%6.48%-18.16%21.51%26.4%23.2%19.62%26.34%18.16%-4.9%11.14%14.99%-47.86%35.41%40.25%42.72%34.19%
Net Income Growth %-2886.81%447.28%92.23%-163.11%76.27%-69.59%68.65%57.02%-272.55%199.79%-796.68%-130.49%201.72%-646.51%-172.72%176.64%-217.99%-11.73%2.23%-6.89%-14.78%53.08%499.04%-145.95%0.4%159.1%-336.76%37.67%28.98%55.07%287.01%
Net Income (Continuing)-1.21B122.1M-72M-611M-212M-937M-559M-1.78B-4.14B2.4B-2.41B-265.07M880M-863.6M-116M159.56M-208.19M176.46M199.9M195.54M210M257.01M166.21M-40.34M87.8M87.45M-84.44M62.5M45.4M35.2M22.7M
Discontinued Operations0000000000000000000000000000000
Minority Interest977M929.31M957M940M952M72M70M73M82M95M106M119M122.3M114.6M00000000000000000
EPS (Diluted)-3.190.43-0.13-1.62-0.62-2.61-1.57-5.06-11.868.59-6.94-0.773.10-2.70-0.380.50-1.061.161.521.211.541.791.20-0.170.870.92-1.030.680.650.500.32
EPS Growth %-2758.41%430.77%91.98%-161.29%76.25%-66.24%68.97%57.34%-238.07%223.78%-801.3%-124.84%214.81%-610.53%-176%147.17%-191.38%-23.68%25.62%-21.43%-13.97%49.17%805.88%-119.54%-5.43%189.32%-251.47%4.62%30%56.25%300%
EPS (Basic)-0.43-0.13-1.62-0.62-2.61-1.57-5.06-11.868.63-6.94-0.783.16-2.70-0.380.53-1.061.161.521.211.541.791.20-0.170.911.02-1.150.720.650.500.32
Diluted Shares Outstanding372.8M375M368M364.9M362M358.9M355M352.1M349.87M351.8M347.3M347.3M341.5M321M305.45M326.12M195.81M158.51M159.73M160.88M160.08M159.68M160.99M160.12M160.46M150.69M143.51M108.17M106.56M100.57M98.7M
Basic Shares Outstanding372.8M370.9M368M365.43M362M358.9M355M352.1M349.87M350.2M347.12M342.7M335.4M320.78M305.26M304.65M195.81M158.24M159.73M160.84M160.06M159.43M160.99M158.43M151.96M136.93M128.82M102.54M106.56M100.57M98.7M
Dividend Payout Ratio-----------------90.72%77.96%178.83%37.16%33.58%---------

Key Metrics

Growth RegimeStable
ProfitabilityStrained
Balance SheetVulnerable
Cash FlowMixed
Top Statement Risk

Debt service and litigation

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Amid Structural Shifts

According to recent financial filings, BHC has maintained a relatively consistent revenue growth trajectory, with quarterly figures hovering around the 10% mark, though the 2026Q1 revenue of $2.5B suggests that the company's top-line expansion remains sensitive to the ongoing integration and divestiture of its Bausch + Lomb assets.

The revenue growth appears to be supported by the recurring nature of the vision care portfolio, yet the volatility in quarterly performance indicates that transactional segments like surgical equipment remain susceptible to broader market conditions. Investors should monitor whether this growth is organic or driven by pricing adjustments, as the current pace may not be sufficient to offset the company's significant interest obligations.

Margin Compression and Cost Volatility

As reported in historical income statements, BHC's gross margin has experienced a notable contraction from over 70% in 2024 to 61.2% in 2026Q1, reflecting potential shifts in product mix and increased manufacturing costs within the company's vertically integrated eye-health and specialty pharmaceutical segments.

The decline in gross margin suggests that the firm's pricing power may be under pressure, possibly due to increased competition or changes in the reimbursement landscape for its core GI assets. This compression warrants further investigation into whether the company can maintain its historical profitability levels without sacrificing market share in its high-margin specialty lines.

Operating Leverage Constrained by Debt

Based on reported figures, BHC's operating income of $513.8M in 2026Q1 highlights a persistent struggle to translate gross profit into bottom-line earnings, as the company's substantial interest expense continues to act as a primary drain on net profitability, resulting in a net margin of -56.4%.

The disparity between operating margins and net margins underscores the company's heavy reliance on debt financing, which appears to limit its ability to reinvest in R&D or pursue strategic growth initiatives. The current structure suggests that operational improvements are being largely neutralized by the cost of servicing the existing debt stack.

Earnings Volatility and Non-Operating Items

Analysis of the income statement reveals that BHC's net income is frequently impacted by significant non-operating items, as evidenced by the $1.4B net loss in 2026Q1, which contrasts sharply with the positive earnings reported in previous quarters, suggesting high sensitivity to accounting adjustments and impairment charges.

The inconsistency in EPS, ranging from significant losses to modest gains, indicates that the company's reported earnings may not be a reliable indicator of underlying operational health. Investors should be cautious of these fluctuations, as they appear to be driven more by financial restructuring and asset valuation changes than by core business performance.

Litigation Risks and Margin Sustainability

As noted in recent regulatory disclosures, the ongoing patent litigation surrounding Xifaxan poses a material threat to BHC's future cash flows, potentially undermining the stability of the Salix segment, which currently serves as a critical profit engine for the entire organization's debt-servicing capabilities.

A negative outcome in these legal proceedings could force a rapid and painful deleveraging process, as the company would lose its most reliable source of high-margin revenue. The market's current valuation may be underestimating the binary risk associated with these patent challenges, which could fundamentally alter the company's long-term viability.

BHC — Frequently Asked Questions

Quick answers to the most common questions about buying BHC stock.

What was Bausch Health Companies Inc.'s (BHC) revenue in 2025?

For fiscal year 2025, Bausch Health Companies Inc. (BHC) reported total revenue of $10.45B. This represents a 15631.5% increase compared to $66.4M in 1996.

Is Bausch Health Companies Inc. (BHC) profitable?

Bausch Health Companies Inc. (BHC) is profitable, generating $159.7M in net income for the fiscal year ending 2025 with a net profit margin of 1.5%.

What is Bausch Health Companies Inc.'s operating profit margin?

Bausch Health Companies Inc. (BHC) reported an operating income of $2.22B, resulting in an operating profit margin of 21.3%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Bausch Health Companies Inc.'s gross profit and gross margin?

Bausch Health Companies Inc. (BHC) generated $6.36B in gross profit for the year, representing a gross profit margin of 60.9%. This demonstrates the company's core pricing power and production efficiency.